Hepatitis C Therapy With Interferon-α and Ribavirin Reduces CD4 T-Cell–Associated HIV-1 DNA in HIV-1/Hepatitis C Virus–Coinfected Patients
Identifieur interne : 000962 ( Ncbi/Merge ); précédent : 000961; suivant : 000963Hepatitis C Therapy With Interferon-α and Ribavirin Reduces CD4 T-Cell–Associated HIV-1 DNA in HIV-1/Hepatitis C Virus–Coinfected Patients
Auteurs : Hong Sun ; Maria J. Buzon ; Amy Shaw ; Randi Karteebahn Berg [Danemark] ; Xu G. Yu ; Sara Ferrando-Martinez ; Manuel Leal ; Ezequiel Ruiz-Mateos ; Mathias LichterfeldSource :
- The Journal of Infectious Diseases [ 0022-1899 ] ; 2013.
Abstract
Combined treatment with interferon alpha (IFN-α) and ribavirin (RBV) can effectively cure HCV infection in a significant proportion of patients, but effects of this regimen on cellular reservoirs for human immunodeficiency virus type 1 (HIV-1) are unknown. Here, we show that treatment with IFN-α/RBV led to a moderate but significant and sustained decline of HIV-1 DNA in CD4 T cells from HIV-1/hepatitis C virus–coinfected patients receiving highly active antiretroviral therapy (n = 12). However, in vitro experiments failed to demonstrate an effect of pharmacological doses of IFN-α on HIV-1 reactivation. Together, these data suggest that treatment with IFN-α/RBV can moderately reduce the reservoir of HIV-1–infected CD4 T cells that persists despite suppressive antiretroviral therapy.
Url:
DOI: 10.1093/infdis/jit628
PubMed: 24277743
PubMed Central: 3982848
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000287
- to stream Pmc, to step Curation: 000287
- to stream Pmc, to step Checkpoint: 000245
Links to Exploration step
PMC:3982848Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hepatitis C Therapy With Interferon-α and Ribavirin Reduces CD4 T-Cell–Associated HIV-1 DNA in HIV-1/Hepatitis C Virus–Coinfected Patients</title><author><name sortKey="Sun, Hong" sort="Sun, Hong" uniqKey="Sun H" first="Hong" last="Sun">Hong Sun</name><affiliation><nlm:aff id="af1"><institution>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University</institution>,<addr-line>Boston</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="af2"><addr-line>Key Laboratory of AIDS Immunology, Department of Laboratory Medicine</addr-line>,<institution>First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line></nlm:aff></affiliation></author><author><name sortKey="Buzon, Maria J" sort="Buzon, Maria J" uniqKey="Buzon M" first="Maria J." last="Buzon">Maria J. Buzon</name><affiliation><nlm:aff id="af1"><institution>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University</institution>,<addr-line>Boston</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="af3"><addr-line>Infectious Disease Division</addr-line>,<institution>Massachusetts General Hospital</institution>,<addr-line>Boston</addr-line></nlm:aff></affiliation></author><author><name sortKey="Shaw, Amy" sort="Shaw, Amy" uniqKey="Shaw A" first="Amy" last="Shaw">Amy Shaw</name><affiliation><nlm:aff id="af1"><institution>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University</institution>,<addr-line>Boston</addr-line></nlm:aff></affiliation></author><author><name sortKey="Berg, Randi Karteebahn" sort="Berg, Randi Karteebahn" uniqKey="Berg R" first="Randi Karteebahn" last="Berg">Randi Karteebahn Berg</name><affiliation><nlm:aff id="af1"><institution>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University</institution>,<addr-line>Boston</addr-line></nlm:aff></affiliation><affiliation wicri:level="1"><nlm:aff id="af4"><addr-line>Infectious Disease Division</addr-line>,<institution>Aarhus University Hospital Skejby</institution>,<addr-line>Aarhus</addr-line>,<country>Denmark</country></nlm:aff><country xml:lang="fr">Danemark</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Yu, Xu G" sort="Yu, Xu G" uniqKey="Yu X" first="Xu G." last="Yu">Xu G. Yu</name><affiliation><nlm:aff id="af1"><institution>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University</institution>,<addr-line>Boston</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ferrando Martinez, Sara" sort="Ferrando Martinez, Sara" uniqKey="Ferrando Martinez S" first="Sara" last="Ferrando-Martinez">Sara Ferrando-Martinez</name><affiliation><nlm:aff id="af5"><addr-line>Laboratory of Immunovirology, Biomedicine Institute of Seville, Division of Infectious Diseases, Microbiology and Preventive Medicine</addr-line>,<institution>Virgen del Rocío University Hospital, University of Seville</institution></nlm:aff></affiliation><affiliation><nlm:aff id="af6"><addr-line>Laboratorio InmunoBiología Molecular</addr-line>,<institution>Hospital General Universitario Gregorio Marañón Madrid</institution></nlm:aff></affiliation><affiliation><nlm:aff id="af7"><institution>Instituto de Investigación Sanitaria Gregorio Marañón</institution>,<addr-line>Madrid</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="af8"><addr-line>Networking Research Center for Bioengineering</addr-line>,<institution>Biomaterials and Nanomedicine (CIBER-BBN)</institution>,<addr-line>Madrid</addr-line></nlm:aff></affiliation></author><author><name sortKey="Leal, Manuel" sort="Leal, Manuel" uniqKey="Leal M" first="Manuel" last="Leal">Manuel Leal</name><affiliation><nlm:aff id="af5"><addr-line>Laboratory of Immunovirology, Biomedicine Institute of Seville, Division of Infectious Diseases, Microbiology and Preventive Medicine</addr-line>,<institution>Virgen del Rocío University Hospital, University of Seville</institution></nlm:aff></affiliation><affiliation><nlm:aff id="af9"><institution>Consejo Superior de Investigaciones Scientificas</institution>,<addr-line>Madrid</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="af10"><institution>Sevicio Andaluz de Salud</institution>,<addr-line>Sevilla</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ruiz Mateos, Ezequiel" sort="Ruiz Mateos, Ezequiel" uniqKey="Ruiz Mateos E" first="Ezequiel" last="Ruiz-Mateos">Ezequiel Ruiz-Mateos</name><affiliation><nlm:aff id="af5"><addr-line>Laboratory of Immunovirology, Biomedicine Institute of Seville, Division of Infectious Diseases, Microbiology and Preventive Medicine</addr-line>,<institution>Virgen del Rocío University Hospital, University of Seville</institution></nlm:aff></affiliation><affiliation><nlm:aff id="af9"><institution>Consejo Superior de Investigaciones Scientificas</institution>,<addr-line>Madrid</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="af10"><institution>Sevicio Andaluz de Salud</institution>,<addr-line>Sevilla</addr-line></nlm:aff></affiliation></author><author><name sortKey="Lichterfeld, Mathias" sort="Lichterfeld, Mathias" uniqKey="Lichterfeld M" first="Mathias" last="Lichterfeld">Mathias Lichterfeld</name><affiliation><nlm:aff id="af3"><addr-line>Infectious Disease Division</addr-line>,<institution>Massachusetts General Hospital</institution>,<addr-line>Boston</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24277743</idno><idno type="pmc">3982848</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982848</idno><idno type="RBID">PMC:3982848</idno><idno type="doi">10.1093/infdis/jit628</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">000287</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000287</idno><idno type="wicri:Area/Pmc/Curation">000287</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000287</idno><idno type="wicri:Area/Pmc/Checkpoint">000245</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000245</idno><idno type="wicri:Area/Ncbi/Merge">000962</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Hepatitis C Therapy With Interferon-α and Ribavirin Reduces CD4 T-Cell–Associated HIV-1 DNA in HIV-1/Hepatitis C Virus–Coinfected Patients</title><author><name sortKey="Sun, Hong" sort="Sun, Hong" uniqKey="Sun H" first="Hong" last="Sun">Hong Sun</name><affiliation><nlm:aff id="af1"><institution>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University</institution>,<addr-line>Boston</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="af2"><addr-line>Key Laboratory of AIDS Immunology, Department of Laboratory Medicine</addr-line>,<institution>First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line></nlm:aff></affiliation></author><author><name sortKey="Buzon, Maria J" sort="Buzon, Maria J" uniqKey="Buzon M" first="Maria J." last="Buzon">Maria J. Buzon</name><affiliation><nlm:aff id="af1"><institution>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University</institution>,<addr-line>Boston</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="af3"><addr-line>Infectious Disease Division</addr-line>,<institution>Massachusetts General Hospital</institution>,<addr-line>Boston</addr-line></nlm:aff></affiliation></author><author><name sortKey="Shaw, Amy" sort="Shaw, Amy" uniqKey="Shaw A" first="Amy" last="Shaw">Amy Shaw</name><affiliation><nlm:aff id="af1"><institution>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University</institution>,<addr-line>Boston</addr-line></nlm:aff></affiliation></author><author><name sortKey="Berg, Randi Karteebahn" sort="Berg, Randi Karteebahn" uniqKey="Berg R" first="Randi Karteebahn" last="Berg">Randi Karteebahn Berg</name><affiliation><nlm:aff id="af1"><institution>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University</institution>,<addr-line>Boston</addr-line></nlm:aff></affiliation><affiliation wicri:level="1"><nlm:aff id="af4"><addr-line>Infectious Disease Division</addr-line>,<institution>Aarhus University Hospital Skejby</institution>,<addr-line>Aarhus</addr-line>,<country>Denmark</country></nlm:aff><country xml:lang="fr">Danemark</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Yu, Xu G" sort="Yu, Xu G" uniqKey="Yu X" first="Xu G." last="Yu">Xu G. Yu</name><affiliation><nlm:aff id="af1"><institution>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University</institution>,<addr-line>Boston</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ferrando Martinez, Sara" sort="Ferrando Martinez, Sara" uniqKey="Ferrando Martinez S" first="Sara" last="Ferrando-Martinez">Sara Ferrando-Martinez</name><affiliation><nlm:aff id="af5"><addr-line>Laboratory of Immunovirology, Biomedicine Institute of Seville, Division of Infectious Diseases, Microbiology and Preventive Medicine</addr-line>,<institution>Virgen del Rocío University Hospital, University of Seville</institution></nlm:aff></affiliation><affiliation><nlm:aff id="af6"><addr-line>Laboratorio InmunoBiología Molecular</addr-line>,<institution>Hospital General Universitario Gregorio Marañón Madrid</institution></nlm:aff></affiliation><affiliation><nlm:aff id="af7"><institution>Instituto de Investigación Sanitaria Gregorio Marañón</institution>,<addr-line>Madrid</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="af8"><addr-line>Networking Research Center for Bioengineering</addr-line>,<institution>Biomaterials and Nanomedicine (CIBER-BBN)</institution>,<addr-line>Madrid</addr-line></nlm:aff></affiliation></author><author><name sortKey="Leal, Manuel" sort="Leal, Manuel" uniqKey="Leal M" first="Manuel" last="Leal">Manuel Leal</name><affiliation><nlm:aff id="af5"><addr-line>Laboratory of Immunovirology, Biomedicine Institute of Seville, Division of Infectious Diseases, Microbiology and Preventive Medicine</addr-line>,<institution>Virgen del Rocío University Hospital, University of Seville</institution></nlm:aff></affiliation><affiliation><nlm:aff id="af9"><institution>Consejo Superior de Investigaciones Scientificas</institution>,<addr-line>Madrid</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="af10"><institution>Sevicio Andaluz de Salud</institution>,<addr-line>Sevilla</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ruiz Mateos, Ezequiel" sort="Ruiz Mateos, Ezequiel" uniqKey="Ruiz Mateos E" first="Ezequiel" last="Ruiz-Mateos">Ezequiel Ruiz-Mateos</name><affiliation><nlm:aff id="af5"><addr-line>Laboratory of Immunovirology, Biomedicine Institute of Seville, Division of Infectious Diseases, Microbiology and Preventive Medicine</addr-line>,<institution>Virgen del Rocío University Hospital, University of Seville</institution></nlm:aff></affiliation><affiliation><nlm:aff id="af9"><institution>Consejo Superior de Investigaciones Scientificas</institution>,<addr-line>Madrid</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="af10"><institution>Sevicio Andaluz de Salud</institution>,<addr-line>Sevilla</addr-line></nlm:aff></affiliation></author><author><name sortKey="Lichterfeld, Mathias" sort="Lichterfeld, Mathias" uniqKey="Lichterfeld M" first="Mathias" last="Lichterfeld">Mathias Lichterfeld</name><affiliation><nlm:aff id="af3"><addr-line>Infectious Disease Division</addr-line>,<institution>Massachusetts General Hospital</institution>,<addr-line>Boston</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">The Journal of Infectious Diseases</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Combined treatment with interferon alpha (IFN-α) and ribavirin (RBV) can effectively cure HCV infection in a significant proportion of patients, but effects of this regimen on cellular reservoirs for human immunodeficiency virus type 1 (HIV-1) are unknown. Here, we show that treatment with IFN-α/RBV led to a moderate but significant and sustained decline of HIV-1 DNA in CD4 T cells from HIV-1/hepatitis C virus–coinfected patients receiving highly active antiretroviral therapy (n = 12). However, in vitro experiments failed to demonstrate an effect of pharmacological doses of IFN-α on HIV-1 reactivation. Together, these data suggest that treatment with IFN-α/RBV can moderately reduce the reservoir of HIV-1–infected CD4 T cells that persists despite suppressive antiretroviral therapy.</p></div></front></TEI><pmc article-type="brief-report"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">J. Infect. Dis</journal-id><journal-id journal-id-type="publisher-id">jid</journal-id><journal-id journal-id-type="hwp">jinfdis</journal-id><journal-title-group><journal-title>The Journal of Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">0022-1899</issn><issn pub-type="epub">1537-6613</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24277743</article-id><article-id pub-id-type="pmc">3982848</article-id><article-id pub-id-type="doi">10.1093/infdis/jit628</article-id><article-id pub-id-type="publisher-id">jit628</article-id><article-categories><subj-group subj-group-type="heading"><subject>Major Articles and Brief Reports</subject><subj-group subj-group-type="heading"><subject>HIV/AIDS</subject></subj-group></subj-group></article-categories><title-group><article-title>Hepatitis C Therapy With Interferon-α and Ribavirin Reduces CD4 T-Cell–Associated HIV-1 DNA in HIV-1/Hepatitis C Virus–Coinfected Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Hong</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Buzon</surname><given-names>Maria J.</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Shaw</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Berg</surname><given-names>Randi Karteebahn</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Xu G.</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ferrando-Martinez</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="af5">5</xref><xref ref-type="aff" rid="af6">6</xref><xref ref-type="aff" rid="af7">7</xref><xref ref-type="aff" rid="af8">8</xref></contrib><contrib contrib-type="author"><name><surname>Leal</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="af5">5</xref><xref ref-type="aff" rid="af9">9</xref><xref ref-type="aff" rid="af10">10</xref></contrib><contrib contrib-type="author"><name><surname>Ruiz-Mateos</surname><given-names>Ezequiel</given-names></name><xref ref-type="aff" rid="af5">5</xref><xref ref-type="aff" rid="af9">9</xref><xref ref-type="aff" rid="af10">10</xref></contrib><contrib contrib-type="author"><name><surname>Lichterfeld</surname><given-names>Mathias</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib></contrib-group><aff id="af1"><label>1</label><institution>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University</institution>,<addr-line>Boston</addr-line></aff><aff id="af2"><label>2</label><addr-line>Key Laboratory of AIDS Immunology, Department of Laboratory Medicine</addr-line>,<institution>First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line></aff><aff id="af3"><label>3</label><addr-line>Infectious Disease Division</addr-line>,<institution>Massachusetts General Hospital</institution>,<addr-line>Boston</addr-line></aff><aff id="af4"><label>4</label><addr-line>Infectious Disease Division</addr-line>,<institution>Aarhus University Hospital Skejby</institution>,<addr-line>Aarhus</addr-line>,<country>Denmark</country></aff><aff id="af5"><label>5</label><addr-line>Laboratory of Immunovirology, Biomedicine Institute of Seville, Division of Infectious Diseases, Microbiology and Preventive Medicine</addr-line>,<institution>Virgen del Rocío University Hospital, University of Seville</institution></aff><aff id="af6"><label>6</label><addr-line>Laboratorio InmunoBiología Molecular</addr-line>,<institution>Hospital General Universitario Gregorio Marañón Madrid</institution></aff><aff id="af7"><label>7</label><institution>Instituto de Investigación Sanitaria Gregorio Marañón</institution>,<addr-line>Madrid</addr-line></aff><aff id="af8"><label>8</label><addr-line>Networking Research Center for Bioengineering</addr-line>,<institution>Biomaterials and Nanomedicine (CIBER-BBN)</institution>,<addr-line>Madrid</addr-line></aff><aff id="af9"><label>9</label><institution>Consejo Superior de Investigaciones Scientificas</institution>,<addr-line>Madrid</addr-line></aff><aff id="af10"><label>10</label><institution>Sevicio Andaluz de Salud</institution>,<addr-line>Sevilla</addr-line></aff><author-notes><corresp>Correspondence: Mathias Lichterfeld, MD, PhD, Assistant Professor of Medicine, Infectious Disease Division, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA (<email>mlichterfeld@partners.org</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>5</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>25</day><month>11</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>5</month><year>2015</year></pub-date><pmc-comment> PMC Release delay is 12 months and
0 days and was based on the
<volume>209</volume><issue>9</issue><fpage>1315</fpage><lpage>1320</lpage><history><date date-type="received"><day>9</day><month>8</month><year>2013</year></date><date date-type="accepted"><day>7</day><month>10</month><year>2013</year></date></history><permissions><copyright-statement>© The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: <email>journals.permissions@oup.com</email>.</copyright-statement><copyright-year>2013</copyright-year></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="jit628.pdf"></self-uri><abstract><p>Combined treatment with interferon alpha (IFN-α) and ribavirin (RBV) can effectively cure HCV infection in a significant proportion of patients, but effects of this regimen on cellular reservoirs for human immunodeficiency virus type 1 (HIV-1) are unknown. Here, we show that treatment with IFN-α/RBV led to a moderate but significant and sustained decline of HIV-1 DNA in CD4 T cells from HIV-1/hepatitis C virus–coinfected patients receiving highly active antiretroviral therapy (n = 12). However, in vitro experiments failed to demonstrate an effect of pharmacological doses of IFN-α on HIV-1 reactivation. Together, these data suggest that treatment with IFN-α/RBV can moderately reduce the reservoir of HIV-1–infected CD4 T cells that persists despite suppressive antiretroviral therapy.</p></abstract><kwd-group><kwd>HIV-1 reservoir</kwd><kwd>interferon-α</kwd><kwd>ribavirin</kwd><kwd>HIV-1/HCV coinfection</kwd></kwd-group></article-meta></front></pmc><affiliations><list><country><li>Danemark</li></country></list><tree><noCountry><name sortKey="Buzon, Maria J" sort="Buzon, Maria J" uniqKey="Buzon M" first="Maria J." last="Buzon">Maria J. Buzon</name><name sortKey="Ferrando Martinez, Sara" sort="Ferrando Martinez, Sara" uniqKey="Ferrando Martinez S" first="Sara" last="Ferrando-Martinez">Sara Ferrando-Martinez</name><name sortKey="Leal, Manuel" sort="Leal, Manuel" uniqKey="Leal M" first="Manuel" last="Leal">Manuel Leal</name><name sortKey="Lichterfeld, Mathias" sort="Lichterfeld, Mathias" uniqKey="Lichterfeld M" first="Mathias" last="Lichterfeld">Mathias Lichterfeld</name><name sortKey="Ruiz Mateos, Ezequiel" sort="Ruiz Mateos, Ezequiel" uniqKey="Ruiz Mateos E" first="Ezequiel" last="Ruiz-Mateos">Ezequiel Ruiz-Mateos</name><name sortKey="Shaw, Amy" sort="Shaw, Amy" uniqKey="Shaw A" first="Amy" last="Shaw">Amy Shaw</name><name sortKey="Sun, Hong" sort="Sun, Hong" uniqKey="Sun H" first="Hong" last="Sun">Hong Sun</name><name sortKey="Yu, Xu G" sort="Yu, Xu G" uniqKey="Yu X" first="Xu G." last="Yu">Xu G. Yu</name></noCountry><country name="Danemark"><noRegion><name sortKey="Berg, Randi Karteebahn" sort="Berg, Randi Karteebahn" uniqKey="Berg R" first="Randi Karteebahn" last="Berg">Randi Karteebahn Berg</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Ticri/CIDE/explor/TelematiV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000962 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000962 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Ticri/CIDE
|area= TelematiV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:3982848
|texte= Hepatitis C Therapy With Interferon-α and Ribavirin Reduces CD4 T-Cell–Associated HIV-1 DNA in HIV-1/Hepatitis C Virus–Coinfected Patients
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:24277743" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a TelematiV1
| This area was generated with Dilib version V0.6.31. |  |